Sunitinib, everolimus, pembrolizumab, which target c‐kit, serine‐threonine kinase mammalian target of rapamycin (mTOR), and PD‐L1, respectively, demonstrate similar response rates (20%) and PFS (4‐5 months) for previously treated thymic carcinomas (Table 3), whereas cixutumumab targeting for IGF1R is for previously treated thymoma.22 This evidence concerns the gene IGF1R and thymic carcinoma.